Mergers & Acquisitions ·
Quince Therapeutics completed the acquisition of Orphai Therapeutics on May 18, 2026, adding LAM-001, an inhaled…
QNCXIRulya Therapeutics Inc.
Quince Therapeutics completed the acquisition of Orphai Therapeutics on May 18, 2026, adding LAM-001, an inhaled rapamycin formulation for pulmonary diseases, to its pipeline. Concurrently, the company closed a private placement raising $115 million in gross proceeds and $103.6 million net, with potential additional warrants worth up to $83 million. Cash and cash equivalents totaled $116 million as of June 30, 2026, sufficient to fund operations through the end of 2028. For the quarter ended June 30, 2026, Quince reported a net loss of $75.5 million ($12.31 per share), driven by $59 million in acquired in-process R&D and $9.1 million in non-cash stock-based compensation related to the acquisition. The company initiated a Phase 2b trial for LAM-001 in PH-ILD, with top-line data expected in Q1 2028, while BOS data is anticipated in Q1 2027. Quince Therapeutics operates as a clinical-stage biopharmaceutical company developing disease-modifying therapies for serious underserved pulmonary diseases.